Key Facts on AstraZeneca

AstraZeneca Canada

Canadian president and CEO: Mark Jones.
Powerful product portfolio including many world leaders and a range of high potential therapies for treating cancer (Casodex^®, Arimidex^® and Iressa^®), gastrointestinal disease (Nexium^®), asthma (Symbicort^®), hypertension (Atacand^®), high cholesterol (Crestor^®), migraine (Zomig^®) and schizophrenia (Seroquel^®).

One of the world's leading pharmaceutical companies.
Formed April 1999, by a merger between Astra AB (Sweden) and Zeneca PLC (U.K.).
Employ 64,000 people across the globe.
Active worldwide with sales in over 150 countries, manufacturing in 20 and research centres in 11.
Formidable product portfolio spanning six major therapeutic areas: cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory.

Over 1,400 employees in Canada.
The majority working at the high-tech facility in Mississauga, Ontario, headquarters for packaging, clinical research, sales, marketing and distribution business.
More than 125 scientists are employed at the state-of-the-art basic pain research centre in Montréal, AstraZeneca Research & Development Montréal.

Spends over Cdn$2 million every week on research and development in Canada.
Strong R&D pipeline, including a number of significant innovations.
A significant portion of this funding is invested in R&D Montreal where leading-edge basic research in pain treatment is conducted.

In addition to many research grants and awards, AstraZeneca Canada is proud to sponsor nine Chairs at seven of Canada's leading universities.
AstraZeneca has made a commitment to Imagine’s corporate giving standards, donating a minimum of one per cent of pre-tax profits to community organizations and encouraging employee volunteering.
Through AstraZeneca’s internal Side by Side program, the company acknowledges and financially supports the charitable organizations with which employees are personally involved.